Key result
Molecular testing identifies FUS rearrangements in ~100% of EWSR1-negative adamantinoma-like Ewing sarcoma cases.
Why the study?
Adamantinoma-like Ewing sarcoma (ALES) is typically associated with EWSR1 rearrangements, but cases lacking EWSR1 rearrangements and their molecular characteristics were not well described.
Case Report (n=6)
Adamantinoma-like Ewing sarcoma may harbor FUS rearrangements, including FUS::FLI1 fusions, expanding the molecular diagnostic considerations for this rare malignancy.
FUS testing may be considered in EWSR1-negative adamantinoma-like Ewing sarcoma; leaves open effects on classification and outcomes.
Adamantinoma-like Ewing sarcoma (ALES) is a rare malignancy currently considered a variant of Ewing sarcoma with most known cases harboring EWSR1 rearrangements. Herein we present a series of 6 cases of EWSR1 -negative ALES. The tumors arose in the sinonasal tract (n=3), major salivary glands (submandibular gland=1; parotid=1), and anterior mediastinum (n=1) in patients ranging from 25 to 79 years of age. Most tumors were basaloid in appearance, growing in large nests separated by interlobular fibrosis without overt squamous pearls. However, 1 case closely resembled a well-differentiated neuroendocrine tumor with uniformly round nuclei, eosinophilic cytoplasm, and trabecular architecture. All cases were diffusely positive for pan-cytokeratin, p40 or p63, and CD99. A subset of cases showed diffuse reactivity for synaptophysin, including 1 sinonasal tumor which also demonstrated sustentacular S100 protein expression. Molecular testing showed FUS rearrangements in all cases. Gene partners included known ETS family members FEV (n=2) and FLI1 (n=1). Our results expand the molecular diagnostic considerations for ALES to include FUS rearrangements. We also show that ALES may harbor FUS :: FLI1 fusion, which has not been previously reported in the Ewing family of tumors. Furthermore, ALES may show unusual histologic and immunophenotypic features that can overlap with olfactory carcinoma including S100-positive sustentacular cells. ALES should be considered in the diagnostic differential of small round cell tumors and tumors with neuroendocrine differentiation with immunohistochemical workup to include p40 and CD99/NKX2.2.
No takes yet. Share an insight, caveat, or question.
Palsgrove et al. (2023) conducted a case report in Adamantinoma-like Ewing sarcoma (ALES) (n=6). FUS rearrangements was evaluated on Presence of FUS rearrangements. All 6 cases of EWSR1-negative adamantinoma-like Ewing sarcoma harbored FUS rearrangements, expanding the molecular diagnostic considerations for this rare malignancy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: